AbbVie to Invest $195M in Chicago Manufacturing Plant

AbbVie will invest $195 million in its North Chicago, Illinois, manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the U.S.

The new North Chicago API facility will expand AbbVie’s chemical synthesis capabilities in the U.S., supporting domestic production of current and next-generation neuroscience, immunology and oncology medicines.

This expansion is part of AbbVie’s previously announced commitment to invest more than $10 billion of capital in the U.S. to broadly support innovation and expand critical manufacturing capabilities and capacity.

“Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs,” said Robert A. Michael, Chairman and CEO, AbbVie. “This is an important step to maintain U.S. leadership in pharmaceutical innovation and deliver next-generation medicines that make a remarkable impact on patients’ lives.”

Construction of the new North Chicago API facility will begin in fall 2025, with the site projected to be fully operational in 2027.